Eupraxia Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Selling, General & Admin	17.1	10.92	7.48	3.99	6.48	Upgrade
Research & Development	21.33	16.08	20.36	13.63	7.58	Upgrade
Operating Expenses	38.43	27	27.85	17.62	14.15	Upgrade
Operating Income	-38.43	-27	-27.85	-17.62	-14.15	Upgrade
Interest Expense	-	-0.96	-1.17	-0.98	-0.97	Upgrade
Interest & Investment Income	1.41	1.16	0.86	0.43	0.05	Upgrade
Currency Exchange Gain (Loss)	-1.56	-0.16	0.07	0.24	0.16	Upgrade
Other Non Operating Income (Expenses)	-	1.2	-0.84	-1.06	-4.74	Upgrade
EBT Excluding Unusual Items	-38.58	-25.76	-28.92	-18.98	-19.65	Upgrade
Gain (Loss) on Sale of Assets	-0	0.02	-0	-0.01	-	Upgrade
Other Unusual Items	-	-	-	-	0.42	Upgrade
Pretax Income	-38.59	-25.74	-28.93	-18.99	-19.23	Upgrade
Income Tax Expense	0.02	0	0.04	-	-	Upgrade
Earnings From Continuing Operations	-38.61	-25.74	-28.97	-18.99	-19.23	Upgrade
Minority Interest in Earnings	0.03	0.24	0.75	0.5	0.3	Upgrade
Net Income	-38.58	-25.5	-28.22	-18.49	-18.93	Upgrade
Preferred Dividends & Other Adjustments	2.53	0.43	-	-	-	Upgrade
Net Income to Common	-41.11	-25.93	-28.22	-18.49	-18.93	Upgrade
Shares Outstanding (Basic)	40	34	24	19	12	Upgrade
Shares Outstanding (Diluted)	40	34	24	19	12	Upgrade
Shares Change (YoY)	17.76%	40.52%	25.21%	55.45%	102.75%	Upgrade
EPS (Basic)	-1.03	-0.76	-1.17	-0.96	-1.53	Upgrade
EPS (Diluted)	-1.03	-0.76	-1.17	-0.96	-1.53	Upgrade
Free Cash Flow	-29.14	-30.1	-20.82	-14.63	-12.06	Upgrade
Free Cash Flow Per Share	-0.73	-0.89	-0.86	-0.76	-0.97	Upgrade
EBITDA	-38.27	-26.89	-27.73	-17.51	-14.11	Upgrade
D&A For EBITDA	0.16	0.11	0.11	0.11	0.04	Upgrade
EBIT	-38.43	-27	-27.85	-17.62	-14.15	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.